Study Summary
This trial is testing a combination of two immunotherapy drugs, nivolumab and anti-IL-8, with radiation to see if it is safe and if it can help treat cancer.
- Melanoma
- Renal Cell Carcinoma
- Unresectable Solid Tumors
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
1 Primary · 6 Secondary · Reporting Duration: Up to 3 years
Trial Safety
Phase-Based Safety
Awards & Highlights
Trial Design
1 Treatment Group
Nivolumab (Anti-PD-1) + BMS-986253 (Anti-IL-8) + SBRT
1 of 1
Experimental Treatment
50 Total Participants · 1 Treatment Group
Primary Treatment: BMS-986253 · No Placebo Group · Phase 1
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 3 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Is recruitment still possible for this research endeavor?
"According to the data hosted on clinicaltrials.gov, this medical study is actively enrolling patients. The initial posting of the trial was October 8th 2021 and it has since been revised in April 19th 2022." - Anonymous Online Contributor
What primary purpose does BMS-986253 serve for medical practitioners?
"BMS-986253 has been demonstrated to be efficacious at treating malignant neoplasms, unresectable melanoma, and squamous cell carcinomas." - Anonymous Online Contributor
Has BMS-986253 ever been tested in a prior medical experiment?
"At this moment, 717 research studies are underway concerning BMS-986253. Of those ongoing trials, 82 have reached Phase 3 and the primary investigation hub is in Basel, BE. There are 40281 medical centres across the globe administering tests for this treatment." - Anonymous Online Contributor
Has BMS-986253 received regulatory clearance from the FDA?
"The limited clinical data available suggests that BMS-986253 is relatively safe, thus receiving a score of 1." - Anonymous Online Contributor
Is this trial a pioneering venture in its field?
"Presently, 717 studies of BMS-986253 are ongoing in 2356 cities across 49 countries. Ono Pharmaceutical Co. Ltd first conducted a trial for the drug back in 2012; this initial study involved 659 patients and completed both Phase 1 & 2 clinical evaluation stages. Since then, 258 follow-up investigations have been concluded." - Anonymous Online Contributor
How many participants are engaged in this experiment?
"Affirmative. Information hosted on clinicaltrials.gov attests that this clinical study, which was originally made available on October 8th 2021, is currently welcoming applicants. The project requires 50 participants from 1 medical centre to be enrolled." - Anonymous Online Contributor